A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis

Vaccine

Volumn 20, Issue 7-8, 2002, Pages 1226-1231

  Gonzalo, Rosa M ^a   Del Real, Gustavo ^a   Rodriguez, Juan R ^a   Rodriguez, Dolores ^a   Heljasvaara, Ritva ^a   Lucas, Pilar ^a   Larraga, Vicente ^b   Esteban, Mariano ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Leishmania infantum; Leishmaniasis; Recombinant vaccinia virus

Indexed keywords

DNA VACCINE; RECOMBINANT VACCINE; VIRUS DNA;

ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA VECTOR; FEMALE; FOOT PAD; IMMUNE RESPONSE; INFECTION PREVENTION; LEISHMANIA INFANTUM; LEISHMANIASIS; MOUSE; MOUSE STRAIN; NONHUMAN; PARASITE; PRIORITY JOURNAL; PROMASTIGOTE; SPLEEN CELL; TH1 CELL; VIRUS EXPRESSION; VIRUS LOAD;

ANIMALS; CRYSTALLINS; FEMALE; IMMUNIZATION; INTERFERON TYPE II; INTERLEUKIN-10; LEISHMANIA INFANTUM; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; NAD(P)H DEHYDROGENASE (QUINONE); PROTOZOAN VACCINES; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA; ZETA-CRYSTALLINS;

EID: 0037081386     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00427-3     Document Type: Article

References (28)

1. Control of leishmaniasis
2. Canine leishmaniasis in the Mediterranean area and its implications for human leishmaniasis
3. Genetic vaccination against leishmaniasis
4. Membrane glycoprotein M-2 protects against L. amazonensis infection
5. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis
6. Expression cloning of a protective Leishmania antigen
7. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major
8. DNA vaccines
9. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
10. Applications of pox virus vectors to vaccination: An update
11. Recombinant vaccinia viruses expressing GP46/M2 protect against Leishmania infection
12. Recombinant viruses expressing a human malaria antigen elicit protective immune CD8+ T cell responses in mice
13. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
14. Enhanced CD8+ T cell response to HIV-env by combined immunisation with influenza and vaccinia virus recombinants
15. Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum
16. Expression of the firefly luciferase gene in vaccinia virus: A highly sensitive gene marker to follow virus dissemination in tissues of infected animals
17. Vaccinia virus expression vector: Coexpression of beta-galactosidase provides visual screening of recombinant virus plaques
18. Culture microtitration: A sensitive method for quantifying Leishmania infantum in tissues of infected mice
19. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T cell-mediated protective immunity against malaria
20. Induction of CD8+ T cells using heterologous prome-boost immunisation strategies
21. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis: Evidence for the expansion of distinct helper T cell subsets
22. Production of interferon gamma, interleukin 2 and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis
23. Patterns of cytokine secretion in murine leishmaniasis: Correlation with disease progression or resolution
24. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
25. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: A potential immunoregulatory role for CD8+ T cells
26. A striking property of vaccinia viruses: Efficient inducers of in vivo expansion of primed CD8+ T cells
27. Use of DNA priming and vaccinia virus boosting to trigger an efficient immune response to HIV-1 gp120